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Abstract
Background This study examined the safety and effective-
ness of the procedural sedation analgesia (PSA) technique
carried out in the emergency department (ED) of a
university hospital over a period of 1 year. The research
was done to compare the effectiveness and efficacy of
moderate sedation of fentanyl combined with either mid-
azolam or propofol for any brief, intense procedure in the
ED setting.
Aims The objectives were to observe the occurrence of
adverse events in subjects undergoing PSA for intense and
painful procedures in the emergency department and to
implement the use of capnography as a method of
monitoring the patients when they were under PSA.
Methods Forty patients were selected for this study. They
were randomly divided into two equal groups using the
computer-generated random permuted blocks of four
patients. Twenty patients were grouped together as group
A and the remaining 20 patients as group B. Drugs used
were single blinded to prevent any bias. Drug A was
propofol and fentanyl, while drug B was midazolam and
fentanyl. The procedures involved included orthopedic
manipulation such as reduction of fractures, reduction of
dislocated joints, abscess drainage, wound debridement,
laceration wound repair and cardioversion. All of the
subjects were monitored for their vital signs and end tidal
carbon dioxide level every 10 min till the PSA was
completed. The duration of stay in the ED was documented
when the subjects had completed the procedure and were
released from the department.
Result Of the study population, 75.6% were males. The
mean age was 37.8 years (95% CI 33.2, 39.8). None of the
patients developed any major complications while under
PSA. The vital signs pre-, intra- and post-procedure were
not significantly different in either the propofol or miz-
adolam groups (p value >0.05).
Conclusion This study had proven that there was no
difference in adverse event occurrence between the studied
drugs during PSA. Propofol can be recommended for use in
PSA if the operator is well trained and familiar with the
drug.
Keywords Procedural sedation analgesia.Midazolam.
Propofol.Emergency department
Introduction
Patients who attend the emergency department (ED) for any
form of trauma and critically ill conditions frequently
present with physical or mental pain and agitation. These
stresses may be associated with tremendous neuro-humoral
elevation of plasma catecholamine, cortisol, glucose, anti-
diuretic hormone and acute phase protein levels [1, 2]. This
elevation can cause significant tachycardia, hypertension,
vasoconstriction, increase oxygen consumption, blunting of
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DOI 10.1007/s12245-010-0162-3immune response, and salt and water retention. In addition,
these patients are extremely anxious. During these critical
situations, procedures may be indicated that require patients
to be subjected to some form of chemical induction to
facilitate the procedure planned either to save their lives or
salvage the remaining functioning organs or limbs. A
collective decision needs to be made to choose the most
appropriate form of chemical induction for the purpose of
analgesia or sedation; usually patients receive the latter [3,
4]. The superiority of one of these drugs and the lack of
potentially dangerous adverse reactions would determine
the appropriate choice in the ED setting. The main goal of
procedural sedation and analgesia (PSA) is to give patients
some relief from both pain and anxiety with minimal
adverse events. This technique has to be effective in
reducing the stress response and improving patient compli-
ance with a procedure [5–7].
Commonly benzodiazepine, such as diazepam or mid-
azolam, is used as an agent for the PSA. Pharmacologically,
it takes up to 45 min for the patients to recover fully and be
discharged, and adverse events such as respiratory depres-
sion are a known occurrence [8, 9]. This study examined an
alternative agent to PSA, namely propofol. We already
know that propofol has a similar mode of action to
benzodiazepine, but with a much shorter duration of
action [10]. The use of an effective short-acting drug in
PSA relieves patients from numerous unpleasant side
effects that are commonly seen with the use of conven-
tional long-acting diazepam. We conducted a randomized
controlled trial to compare the adverse events between
propofol and midazolam during PSA in adult patients who
attended the emergency department. The study was
approved by the University Hospital Ethics and Research
Committee.
Objectives
The purpose of the study was to compare the outcomes
between a combination of fentanyl and propofol with
fentanyl and midazolam on subjects during and after PSA.
The outcome measurements were:
1. Vital signs:
a. Systolic and diastolic blood pressure
b. Respiratory rate
c. Heart rate
d. Mean arterial pressure (MAP)
e. Oxygen saturation (SPO2)
2. End tidal carbon dioxide (EtCO2): to implement
microstream capnography during PSA as a method of




The use of combined fentanyl and propofol has no
difference in adverse event occurrence over fentanyl and
midazolam for PSA.
2. Population
Patients who fulfill the criteria for PSA
3. Intervention




This was a randomized single-blinded control trial carried
out in the ED of a university hospital over a period of
12 months. The hospital is a regional tertiary referral center
with an attendance rate to the emergency department
exceeding 60,000 per year. It is also a teaching hospital
responsible for both undergraduate student and residency-
based training in many specialized fields including emer-
gency medicine. The proposal for this study was presented
to the Department Review Board and Hospital Ethics
Committee, and we received approval to proceed. The
reference for the certificate of approval is USMKK/PPSP®/
JK P&E. A short-term grant was also approved for
conducting the study.
All 40 patients were selected by convenience sampling,
and further randomization into two groups was carried out
by using the computer-generated random permuted blocks
of four patients. All patients recruited did not know which
drug they would receive. Each group would receive either
drug A or drug B. The drugs used were single blinded.
They were supplied by the pharmacy department, wrapped
individually and placed in an envelope. Each envelope was
sealed and labeled accordingly as drug A or drug B. The
operators, emergency physicians and residents in Emergen-
cy Medicine, including the main researcher, were unaware
of the exact drug to be given until the envelope was
opened. Administration of the medications to the patients
required precise calculation of the dosage based on the
subject's body weight.
Inclusion criteria
All adult patients who presented to the Emergency
Department for either brief or intensely painful procedures,
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immobilization were carefully evaluated for suitability to
be recruited in this pilot study. The suitability of the
subjects was evaluated based on the following criteria:
1. All trauma (except head injury) and non-trauma adult
patients
2. All adult patients who were able to give verbal and
written consent to participate in the study.
3. All patients who were indicated to have procedural
sedation.
4. All patients with physical status of ASA I and II
Patients were numbered and matched to the drugs under
study. Detailed explanations regarding the study and the
drugs to be used for PSA were provided to all subjects
before getting both verbal and written consent. The
explanations given included the effects and the side effects
of the drugs under study. Patients also received explan-
ations about the procedure that would take place during the
PSA. Both verbal and written consents were obtained as
required by the University Research Ethical Committee.
Standard monitoring (pre-, intra- and post-procedure) of
systolic and diastolic blood pressure, heart rate, respiratory
rate, end tidal carbon dioxide and O2 saturation were
carried out on each patient selected to be in the study
(parameters for adverse events). In this study we used nasal
prong microstream capnography for monitoring the cardio-
respiratory status of patients [11]. The capnographic tubing
was attached to a Datascope® monitor manufactured in the
USA. The machine was calibrated daily by the same
investigator. The vital signs were charted in the case report
form every 5 to 10 min despite continuous monitoring of
these parameters. All of the selected patients were to be
given intravenous normal saline before the procedure at a
rate of 500 ml/2 h to avoid the risk of significant
hypotension, and this was part of the fasting (nothing by
mouth) procedure prior to the procedure.
Patients were randomly allocated to one of the two
groups:
1. Group A: Subjects received IV fentanyl 1 mcg/kg as a
titration dose and propofol 1 mg/kg followed by
propofol 0.5 mg/kg if needed (n=20).
2. Group B: Subjects received IV fentanyl 1 mcg/kg as a
bolus dose and a titration dose of midazolam 0.1 mg/kg
and 0.1 mg/kg if needed (n=20).
A modified Ramsay Scoring System was used to
monitor the drug titration to achieve either grade 3 or 4
on the scoring system (Table 1). Vital signs were monitored
and recorded every 5–10 min until the procedure ended.
Any cardiorespiratory adverse reactions during the proce-
dures were closely observed, documented and managed
according to departmental guidelines. The specialists,
residents, medical officers and paramedics in the depart-
ment were given adequate briefing about the study. This
included the issues related to the subject recruitment
criteria, the techniques to be carried out, vital sign
monitoring and documentation, and data collection through
a series of presentations and group discussions 2 months
prior to the commencement of the study.
For statistical analysis, the non-parametric test was used
due to the small sample size and the non-Gaussian
distribution. The Mann-Whitney U test was used to
compare the two groups.
Results
Comparison of demographic and other initial parameters for
both groups is shown in Table 2. The senior resident (final
year residents) in the Emergency Medicine Department and
the specialist emergency physicians performed 75% (n=30)
and 25% (n=10) of the procedures, respectively. None of
the patients in either group developed any adverse events
during and after the procedures. No significant drops in
blood pressure, heart rate, respiratory rate, end tidal CO2
and pulse oximetry were observed during and after the
procedures. Even though a few parameters, such as MAP,
SBP and DBP, dropped intra-procedure, these values
normalized post-procedure, and the changes were statis-
tically insignificant within and between the groups
(Tables 3 and 4).
The end tidal carbon dioxide in the propofol group did
not show much variation between the pre- and intra-
procedural readings. The means (SD) of pre-procedural
and intra-procedural end tidal carbon dioxide were 36.05
(6.57) and 37.80 (4.96), respectively. The post-procedural
mean (SD) on the other hand was 36.75 (5.46) with the
intra-procedural p value being 0.775. In the midazolam
group, the means (SD) of end tidal carbon dioxide both pre-
procedure and intra-procedure were 34.45 (7.82) and 35.05
(8.97), respectively (p=0.775). After the procedure, the
mean (SD) of end tidal carbon dioxide was 36.70 (7.20).
Similarly, no statistical difference in ETCO2 was found
between the two study groups.
Table 1 Modified Ramsay Scoring System
Score Response
1 Anxious or restless or both
2 Cooperative, orientated and tranquil
3 Responding to commands
4 Brisk response to stimulus
5 Sluggish response to stimulus
6 No response to stimulus
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The main goal of PSA is to give patients some relief from
both pain and anxiety. In addition, this technique has been
clinically shown to be effective in reducing the stress
response and improving patient compliance with undergo-
ing a procedure. In general, procedural sedation should be
accompanied by analgesia simply because analgesia is able
to decrease the stressful effect. This could result in a low
requirement for sedatives [12].
The use of PSA has generated much interest and debate,
although the technique has been widely practiced in many
settings that previously were regarded as being in the
domain of anesthesiology [13, 14]. PSA offers many
advantages. Firstly, patients are able to maintain conscious-
ness while undergoing an unpleasant procedure. Their
tolerance of such painful procedures makes them able to
cooperate with the care providers, thereby increasing the
compliance further. In addition, this technique does not
greatly disrupt the patient’s daily activities. Upon being
discharged from the hospital, the patients can resume their
jobs and daily activities within a relatively short period of
time with minimal discomfort. The settings found to be of
benefit to patients undergoing PSA include procedures in
dentistry (dental and oral surgery), radiology, medicine
(bronchoscopy, endoscopy, cardiac studies, pacemaker
placement) and gynecology (in vitro fertilization). This
approach is also being utilized in the outpatient setting [15–
17]. In the ED, procedural sedation and analgesia have been
widely indicated in overtly anxious patients undergoing
procedures such as repair of complicated lacerations,
reduction of fractures, application of plaster casts, incision
and drainage of abscesses and wound care, thus making it a
technique of choice.
Despite the promising outcomes and benefits, some
precautions are still required. Adverse events such as
Table 3 Comparing propofol and midazolam by SBP, DBP and MAP
Variables Propofol Propofol Midazolam Midazolam p-value
Mean (SD) Median (IQR) Mean (SD) Median (IQR)
Systolic blood pressure
Pre-procedure 134.00 (16.27) 127.50 (120.00, 143.75) 131.50 (15.31) 130.00 (120.00, 140.00) 0.679
Intra-procedure 115.50 (10.50) 120.00 (110.00, 120.00) 121.00 (17.59) 120.00 (110.00, 133.00) 0.388
Post-procedure 122.50 (13.43) 120.00 (111.25, 130.00) 120.75 (15.25) 120.00 (110.00, 128.75) 0.608
Diastolic blood pressure
Pre-procedure 75.30 (9.27) 75.00 (70.00, 80.00) 75.25 (11.53) 70.00 (70.00, 80.00) 0.731
Intra-procedure 64.75 (8.66) 65.00 (60.00, 70.00) 65.75 (11.62) 67.50 (60.00, 70.00) 0.868
Post-procedure 70.25 (6.52) 70.00 (60.00, 78.75) 73.00 (15.25) 70.00 (61.25, 78.75) 0.989
MAP
Pre-procedure 94.45 (9.88) 94.50 (87.10, 100.00) 94.66 (10.31) 93.30 (87.10, 99.17) 0.765
Intra-procedure 82.00 (8.70) 81.65 (76.70, 89.17) 83.84 (12.27) 85.00 (74.97, 89.17) 0.744
Post-procedure 87.76 (9.41) 86.70 (80.00, 92.90) 87.73 (12.44) 86.70 (80.82, 92.25) 0.733
Table 2 Demographic data and vital sign parameters for both treatment groups
Demography/vital parameters Group A (propofol and fentanyl) Group B (midazolam and fentanyl) p-value
Number of patients 20 20 >0.05
Age (years) 40.6 (95% CI 38.2, 43.3) 35.0 (95% CI 33.2, 37.6) p=0.424
Sex:
Male 15 16 p=0.705
Female 5 4
Systolic BP (mmHg) 127.50 (95% CI 120.00, 143.75) 130.00 (95% CI 120.00, 140.00 p=0.241
Diastolic BP (mmHg) 75.00 (95% CI 70.00, 80.00) 70.00 (95% CI 70.00, 80.00) p=0.093
Mean arterial pressure (mmHg) 94.50 (95% CI 87.10, 100.00) 93.30 (95% CI 87.10, 99.17) p=0.541
Oxygen saturation (%) 99.9 (95% CI 99.80, 100.00) 100.00 (95% CI 100.00, 100.00) p=0.286
End tidal CO2 (mmHg) 38.50 (95% CI 33.25, 40.00) 36.00 (95% CI 33.25,39.00) p=0.662
Heart rate (per minute) 80.00 (95% CI 71.00, 100.00) 80.00 (95% CI 78.00, 96.50) p=0.776
Respiratory rate (per minute) 19.50 (95% CI 18.00, 23.50) 18.00 (95% CI 14.00, 22.00) p=0.334
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PSA are commonly reported. Reasons for the complications
include inexperienced physicians administering the PSA,
improper equipment for monitoring, wrong choice of drugs
and presence of comorbidities that lead to the adverse
events. Patients undergoing PSA must be closely and
continuously monitored to avoid any progression into a
deeper state of sedation [18, 19]. Should this occur, the
actual purpose of PSA would be nullified. Monitoring can
be achieved effectively through visual observation coupled
with the use of a pulse oxymeter and a capnograph. The
procedure can be carried out safely and non-invasively with
the advent of new monitoring strategies. The use of a pulse
oxymeter, for example, coupled with non-invasive moni-
toring of blood pressure optimizes the comfort and care in
patients receiving PSA [20].
The pulse oxymeter has been used to monitor the level
of oxygenation. Since sedation can result in the emergence
of apnea and hypoventilation, failure to detect these
conditions may eventually lead to oxygen desaturation.
The pulse oxymeter has been clinically shown to be a
relevant tool to monitor the existence of oxygen desatura-
tion. The capnograph is another very useful instrument for
recognizing any ventilatory and circulatory problems that
occur during sedation. A capnograph has the capacity to
provide early warnings of apnea and detect the occurrence
of respiratory depression, obstruction or laryngopasm
through the monitoring of end tidal expiratory carbon
dioxide (EtCO2), which can be accurately measured.
Respiratory depression is said to take place when O2
saturation is <90 mmHg, EtCO2 is >50 mmHg or when
there is an absence of EtCO2 waveform [21, 22].
Benzodiazepine such as midazolam has been widely
used in many surgical procedures performed under local
anesthesia. The use of midazolam has been well docu-
mented to enhance patient comfort, improve operating
conditions and most importantly, because of its amnesic
properties, prevent patients from recalling unpleasant
events during the procedure. In addition, midazolam acts
indirectly as a gamma amino butyric acid agonist and is
relatively cardio-respiratory safe. Once administered, it is
rapid in onset and has a short duration of action, which
makes midazolam a very popular drug of choice for PSA
[23]. However, over the last few years, propofol has
emerged quite rapidly as a good agent to be used in PSA
by non-anesthesiologists especially in the ED. When
given intravenously, the effect is almost immediate.
Because of its short half-life, patients on propofol will
recover rapidly.
Propofol has a bronchodilating effect, which makes it an
appropriate drug of choice for patients with bronchial
asthma. Its anti-emetic characteristic gives an added
advantage to minimize post-sedation nausea [24]. However,
propofol reduces the mean arterial pressure (MAP), which
makes it a rather poor choice in patients who develop
hypotension, cardiorespiratory compromise or have head
injuries. Apnea and painful injection are other disadvan-
tages of this drug. It may also cause deep sedation and
analgesia. Deep sedation is said to take place when a
purposeful response is triggered with repeated stimuli,
while moderate sedation is a purposeful response to light
stimuli, e.g., verbal and tactile. Respiratory depression
occurs mainly during deep sedation and not moderate
sedation. In moderate sedation, the protective airway reflex
is intact and thus reduces the risk of aspiration. Respiratory
depression occurs in 19% of patients receiving propofol
alone as compared to those who received fentanyl alone
(20%), while a combination of midazolam with fentanyl
causes respiratory depression in 23% of cases. Due to deep
or over-sedation produced by propofol within the normal
Table 4 Comparisons of respiratory parameters for both treatment groups
Variables Propofol Propofol Midazolam Midazolam p-value
Mean (SD) Median (IQR) Mean (SD) Median (IQR)
Respiratory rate
Pre-procedure 20.30 (4.90) 19.50 (18.00, 23.50) 18.25 (5.00) 18.00 (14.00, 22.00) 0.574
Intra-procedure 20.90 (5.31) 21.50 (16.50, 25.00) 18.40 (4.60) 18.50 (14.50, 21.75) 0.082
Post-procedure 20.10 (5.28) 20.00 (15.00, 24.00) 18.20 (3.59) 18.00 (16.00, 22.00) 0.554
Oxygen saturation
Pre-procedure 99.90 (0.45) 100.00 (100.00, 100.00) 99.85 (0.49) 100.00 (100.00, 100.00) 0.226
Intra-procedure 99.80 (0.89) 100.00 (100.00, 100.00) 99.05 (2.01) 100.00 (99.25, 100.00) 0.106
Post-procedure 99.90 (0.45) 100.00 (100.00, 100.00) 99.80 (0.69) 100.00 (100.00, 100.00) 0.215
ETCO2
Pre-procedure 36.05 (6.57) 38.50 (33.25, 40.00) 34.45 (7.82) 36.00 (33.25, 39.00) 0.558
Intra-procedure 37.80 (4.96) 38.00 (34.25, 42.25) 35.05 (8.97) 39.50 (25.50, 40.75) 0.775
Post-procedure 36.75 (5.46) 38.00 (35.00, 40.00) 36.70 (7.20) 39.00 (33.50, 42.00) 0.606
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other departments [25]. However, Zed et al. and Sipe et
al. have shown that a bolus dose of 1 mg/kg followed
by 0.5 mg/kg (when it is necessary) may reduce both
the hypoxia and apnea compared to the 1.5 mg/kg dose
[26, 27].
This randomized controlled trial study was initiated
primarily to determine the safety of PSA delivery in the ED
setting. In addition, this study also aimed to evaluate the
safety profile and effectiveness of the two sedative
hypnotics, namely propofol and midazolam, which have
been commonly used in patients undergoing PSA. Non-
parametric analysis of data was applied in this study
because of the small sample size and non-Gaussian
distribution in descriptive analysis. Two tests were applied
throughout, namely the Mann-Whitney U test (chi-square)
and Kruskal-Wallis (chi-square and P value). The data were
further analyzed as non-stratified to see the effect without
the confounder, for example, the sex of subjects in the
study and later the stratified analysis where the confounders
were controlled. In this study, age could not be stratified
because the subjects recruited were adults. This trial, which
took 1 year to complete, involved 40 subjects who fully
consented to participate. There were no drop-outs. Clear
instructions and guidelines were strictly adhered to in order
to minimize bias as well as errors in evaluating the safety
profile and efficacy between the two drugs used in PSA. A
standard set of forms was utilized, and all relevant
information required for the study has been clearly
documented.
This study did not show remarkable differences between
the two drugs used, namely propofol and midazolam in
PSA. Both drugs have been found to be safe for use and did
not cause any serious adverse side effects, such as
hypoventilation, hypotension, apnea, hypoxia or allergic
reactions. None of the patients involved in this study
developed any complications throughout the process of
procedural sedation. These findings were consistent and
supported the study done by Hasen et al. on PSA using
intravenous propofol for 48 patients undergoing elective
orthopedic surgery under regional blockade [28]. They
firmly concluded that propofol is a safe and effective drug
to be used in PSA with no respiratory or cardiovascular
depression, or other undesirable adverse effects. Cheol et
al., who conducted a randomized double-blind comparative
study using propofol alone and combined propofol and
midazolam for colonoscopy, found that both propofol alone
and combined propofol and midazolam are safe and
effective [29].
However, some results found in this trial remained
significant and may illustrate the relevant direction of the
future use of these drugs in the emergency department
setting.
Changes in blood pressure recorded during procedural
sedation
There was a significant and relevant variation in blood
pressure before, during and after the procedure. It was
found in this study that propofol caused a marked reduction
in both the systolic and diastolic blood pressures during the
procedure when compared to midazolam. Systolic blood
pressure dropped from a mean (SD) of 134.00 mmHg
(16.27) to 115.50 mmHg (10.50), while the diastolic blood
pressure dropped from a mean (SD) of 75.30 mmHg (9.27)
to 65.00 mmHg (8.66) intra-procedure. After the procedure
ended, the systolic and diastolic blood pressures normalized
to the pre-procedural value (SD) 122.5 mmHg (13.43).
The midazolam group on the other hand showed a
marked elevation in both systolic and diastolic blood
pressures when the procedure was carried out. Prior to the
procedure the mean systolic blood pressure was
121.00 mmHg (17.59) and increased to 131.50 mmHg
(15.31) intra-procedure, then normalized with the comple-
tion of the procedure. A similar observation was seen in the
diastolic blood pressure. The different blood pressure
responses can be explained by the different pharmacody-
namics of the two drugs. Propofol is known to affect the
cardiovascular function of the body system, in particular
compromising the blood pressure mainly through the
vasodilation effect, whereas benzodiazepine is commonly
known to depress more of the respiratory function.
Effects on mean arterial pressure
In this study both propofol and midazolam did not have a
significant effect on the mean arterial pressure when a
procedure was carried out to completion. Despite the changes
in MAP in both drugs under study, during the procedure the p
value showed non-statistical significance (p=0.774). Both
drugs did not result in changes of perfusion to various organs
in the body, further confirming the safety of both drugs.
Effects on respiratory rate
Both propofol and midazolam showed no difference in
respiratory rate during and after procedures (p=0.106). This
could be due to the appropriate titration dose technique
used for the procedural sedation.
Effects on heart rate
There was a slight reduction of heart rate recorded in this
trial during the procedure in the propofol group with a
mean value of 76.40 (16.37), while the pre-procedure mean
heart rate (SD) was 83.55 (16.3). The heart rate reduced
slightly after the completion of the procedure, but did not
110 Int J Emerg Med (2010) 3:105–113reach the pre-procedural level. In the midazolam group, the
heart rate was also found to be reduced during the
procedure stage. The mean heart rate during the procedure
was 79.65 (16.69) and the mean before the procedure (SD)
was 85.45 (13.38). The p value for both groups was 0.795.
End tidal carbon dioxide level
Capnography could provide an accurate assessement of
various aspects of respiratory functions, which included
real-time ventilatory status, endotracheal tube placement
and function, ventilatory circuit disconnection and airway
leaks. This study utilized nasal prong microstream devices,
which measured respiratory gas concentration remotely by
aspirating a small sample of gas from the breathing circuit
through tubing to a sensor located inside the monitor. The
partial pressure of carbon dioxide was kept constant
between the level of 35 mmHg to 45 mmHg. Any adverse
changes or complications in respiratory functions that arise
can be easily detected through capnography. Early detection
would ensure an immediate intervention on the patient [30].
In this study, the end tidal carbon dioxide level in the
propofol group did not show much variation between the
pre- and intra-procedural readings. The means (SD) of pre-
procedural and intra-procedural end tidal carbon dioxide
levels were 36.05 (6.57) and 37.80 (4.96), respectively. The
post-procedural mean was 36.75 (5.46) with an intra-
procedural p value of 0.775. In the midazolam group, the
mean end tidal carbon dioxide levels both pre-procedure
and intra-procedure were 34.45 (7.82) and 35.05 (8.97),
respectively (p=0.77). There were no marked differences in
end tidal carbon dioxide readings between these two drugs.
This was because the doses of both drugs used were
adequately safe, and additional use of capnography moni-
toring of the end tidal carbon dioxide level could provide
early warning should there be evidence of apnea or
hypoventilation. Interventions including repositioning of
the airway can be carried out if there is evidence of
reduction of partial pressure of carbon dioxide. Jennifer et
al. pointed out that capnography is capable of providing
important data regarding airway permeability, cardiac and
circulatory function and ventilator performance, apart from
its ability to evaluate alveolar ventilation. The use of
capnography could replace the need to analyze ABG in a
non-invasive manner [31]. It is important to emphasize that
all subjects in both groups A and B were provided with
continuous oxygen via nasal prong devices throughout the
PSA. In a review done by Vargo, he has stressed the
significance of unrecognized respiratory difficulty and
hypoxemia as a major factor contributing to morbidity
and mortality among patients with PSA in the ambulatory
setting. To overcome these potential risks, he strongly
recommended the use of capnography, which can monitor
and detect any evidence of respiratory compromise early on
with the combined use of pulse oxymetry.
In all the domains of recorded vital signs, it was found to
be insignificant, as shown by the p value of >0.005 on
Mann-Whitney U test. For the respiratory rate in male
subjects, during the procedure a slight reduction of
respiratory rate was observed in the midazolam group from
a mean value of 19.37 (4.96) per minute to 19.12 (4.36)
(p=0.148). There was no similar reduction among males in
the propofol group using stratified Mann-Whitney analysis.
The time interval to discharge for male subjects in the
propofol group was observed to be shorter when compared
to the midazolam group with a mean (SD) value of 30.33
(12.46) as compared to 59.06 (22.7), respectively, with a p
value of 0. 001. In female subjects, the mean (SD) values
for the propofol and midazolam were 26.00 (4.18) and
122.50 (28.16), respectively (p=0.001). There was no
significant change found when the data were stratified
further to look at the effect of the confounder (sex) on the
differences between both propofol and midazolam. Other
studies had shown similar patterns of outcome [32, 33].
Limitations of the study
Several limitations have been identified in this study.
1. Generally the size of the sample recruited was judged
to be small. There were reasons for such a small sample
gathered. This study was carried out for a period of 1
year as part of the clinical exposure for the completion
of the Master program; the sample size was reduced to
an acceptable 40 subjects and had received approval
from the hospital ethics committee. The subjects were
then subdivided equally into two groups comprising 20
subjects each, further reducing the size and thus the
power of this study.
2. During the process of administration of the drugs under
study, the operators were aware of the drugs that were
given to the patients when the envelope was opened.
The operator could easily recognize the types of drugs
given by the different sizes of ampules, the color of the
ampules, the inscription on the ampule and the quantity
of the drug in the ampule. This method did not actually
protect the anonymity of the drug administered and
could possibly have resulted in some level of bias.
3. As a result of the small sample size, the parametric
analysis could not be carried out. The data were
analyzed using the non-parametric Mann-Whitney U
and Kruskal-Wallis analyses.
4. As the main objective of the study was to observe the
outcomes of the drugs used—propofol and midazolam
Int J Emerg Med (2010) 3:105–113 111on vital signs, EtCO2 a n dd u r a t i o no fr e g a i n e d
consciousness—other cofounders like the clinical pro-
cedures and number of doses of the drug top-up were
not included in the data analysis.
Recommendations
This study did not detect any occurrence of hypoxemia,
hypoventilation or apnea in any of the participating subjects
despite evidence indicating that both propofol and mid-
azolam do cause the above complications. This is because
the study used appropriate doses to commence procedural
sedation in the emergency department setting. As both of
these drugs are safe and effective, the main researcher
would like to recommend the following doses to be
administered when performing PSA in the ED setting. For
propofol, the recommended dose is 1 mg/kg body weight as
a bolus dose followed by 0.5 mg/kg if required in a titrating
dose. For midazolam, the recommended dose is 0.1 mg/kg
body weight as a bolus dose followed by 0.1 mg/kg in a
titrating dose when necessary. Although these drugs are
regarded as safe and effective, caution is still needed to
ensure avoidance and minimization of any possible com-
plications. Appropriate attention must be given to all
patients on PSA by continuous monitoring before, during
and after the procedure has been completed. Studies have
indicated that the use of supplemental oxygen could
significantly reduce the magnitude of oxygen desaturation
in any procedure performed when a patient is undergoing
procedural sedation. This fact should be considered
seriously.
A capnograph is a very useful instrument to monitor the
arterial partial pressure of carbon dioxide indirectly during
PSA. It is a very sensitive tool for picking up these changes
at very early stages of hypoventilation, and its detection
accuracy is heavily supported by numerous studies world-
wide. It is recommended that capnography should be used
when PSA is performed in the ED setting. Early interven-
tion could be instituted once abnormal partial pressure of
carbon dioxide is detected.
Finally, all patients planned for PSA in the ED setting
must be thoroughly assessed, which involves detailed
medical history taking in order to prevent the possibility
of developing unexpected complications and delay in
recovery after the procedure has been completed.
Conclusions
Both propofol and midazolam given at the recommended
doses are equally safe and effective in PSA performed in
the ED setting. However, a protocol and clinical guidelines
for practice for PSA need to be developed to ensure this
technique is safe and effective when carried out in the ED.
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